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A B S T R A C T

Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunotherapy that genetically reprograms a patient’s T cells to target and eliminate cancer cells. Tisagenlecleucel is a US Food and Drug Administration-approved CD19-directed CAR T-cell therapy for patients with relapsed/refractory (r/r) B-cell acute
lymphoblastic leukemia and r/r diffuse large B-cell lymphoma. Manufacturing CAR T cells is an intricate process that begins with leukapheresis to obtain T cells from the patient’s peripheral blood. An optimal leukapheresis product is essential to the success of CAR T-cell therapy; therefore, understanding factors that may
affect the quality or T-cell content is imperative. CAR T-cell therapy requires detailed organization throughout the entire multistep process, including appropriate training of a multidisciplinary team in leukapheresis
collection, cell processing, timing and coordination with manufacturing and administration to achieve suitable patient care. Consideration of logistical parameters, including leukapheresis timing, location and patient
availability, when clinically evaluating the patient and the trajectory of their disease progression must be
reﬂected in the overall collection strategy. Challenges of obtaining optimal leukapheresis product for CAR Tcell manufacturing include vascular access for smaller patients, achieving sufﬁcient T-cell yield, eliminating
contaminating cell types in the leukapheresis product, determining appropriate washout periods for medication and managing adverse events at collection. In this review, the authors provide recommendations on
navigating CAR T-cell therapy and leukapheresis based on experience and data from tisagenlecleucel
manufacturing in clinical trials and the real-world setting.
© 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction
Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunocellular therapy that genetically reprograms a patient’s
T cells to target and eliminate cancer cells. Tisagenlecleucel is an
approved CD19-directed CAR T-cell therapy for patients with
relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL)
and r/r diffuse large B-cell lymphoma (DLBCL). Manufacturing CAR T
cells is a complex, multistep process that begins with leukapheresis
to obtain viable T cells from the patient’s peripheral blood. An
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optimal leukapheresis product is critical for the success of
manufacturing; therefore, understanding factors that may affect the
leukapheresis product quality or T-cell content is imperative.
The ﬁrst step in CAR T-cell therapy is leukapheresis for T-cell collection. Procedures that ensure successful collection are necessary for
successful manufacturing and treatment, as higher T-cell numbers in
the leukapheresis product may be associated with achievement of
remission [1]. Previous studies have identiﬁed patient and disease
characteristics associated with low lymphocyte collection efﬁciency
(deﬁned as the lymphocyte count per product volume divided by the
average lymphocyte count per processed peripheral blood volume)
that include advanced age, diagnosis of ALL and high platelet count
prior to leukapheresis [2]. Heavily pre-treated patients may have
high numbers of circulating malignant cells or lymphopenia, which
may be suboptimal for leukapheresis collection. Advancing age
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(every 10 years) and disease factors (including disease type) are associated with low lymphocyte collection efﬁciency (<40%). Although
further data are needed, high platelet count is thought to lead to
occult platelet clumping in the apheresis centrifuge that may result
in narrowing of the mononuclear cell interface. Poorly understood,
but of great interest, is identifying optimal conditions for leukapheresis in very young patients, which will enhance leukapheresis yield
and enable therapy delivery. Real-world data have demonstrated the
efﬁcacy and safety of CAR T-cell therapy in pediatric and young adult
patients with r/r ALL and the ability to collect leukapheresis product
from very young patients (<3 years old) [36].
In addition to volume and quality of the leukapheresis product,
another important factor in the leukapheresis process is the timing
with respect to the patient’s disease trajectory and treatment. Performing leukapheresis prior to beginning salvage therapy to treat disease relapse depends on the clinical status and disease burden of the
patient. Evidence suggests that the choice of salvage therapy may
adversely affect subsequent leukapheresis attempts as it relates to Tcell count recovery and quality [7]. The timing of leukapheresis also
depends on the history of the patient and disease refractoriness. In
patients with highly refractory disease, trying to decrease disease
burden prior to leukapheresis may be counterproductive given the
prior lack of disease response. In pediatric patients with ALL, some
clinicians may consider early leukapheresis in patients with a high
risk of relapse (e.g., Philadelphia chromosome+ and infant ALL) and
when bone marrow transplant outcomes have not been favorable.
Recently, real-world data have demonstrated that leukapheresis and
tisagenlecleucel manufacturing have been successful in patients
<3 years old [8,9]. Patient leukapheresis product collected for tisagenlecleucel manufacturing can be cryopreserved for up to 30
months prior to use in manufacturing. Some centers have established
procedures that facilitate leukapheresis collection earlier in the disease course, which allows ﬂexibility in scheduling, shipping and
patient management [10]. The possibility of long-term storage of cryopreserved leukapheresis product may be beneﬁcial for pediatric
patients with ALL and patients with high-risk non-Hodgkin lymphoma who have early r/r disease prior to additional salvage and
bridging. Notably, if a patient is planning to proceed with allogeneic
stem cell transplant (alloSCT) and requires CAR T-cell therapy for
post-alloSCT relapse, it is unlikely that the leukapheresis product
stored from pre-alloSCT would be utilized, and a fresh collection
would be preferred [11,12]. The optimal timing for cryopreservation
is as soon as possible after collection, but at most within 24 h of collection [10]. Although there are many challenges involved in coordinating leukapheresis, CAR T-cell manufacturing has evolved to be
able to handle a wide range of starting material and continues to
improve. Currently, each CAR T-cell therapy manufacturer provides
speciﬁcations and requirements for collection and handling of leukapheresis product that is acceptable for manufacturing; however, further understanding of how these speciﬁcations and requirements
relate to patient clinical outcomes is needed. As experience is gained
in the real-world setting, it may be possible to increase the ﬂexibility
of leukapheresis speciﬁcations and requirements and may allow further harmonization across different CAR T-cell therapy manufacturers.
Although additional factors related to the cellular characteristics
of the leukapheresis product, such as T-cell subsets and activation/
senescence status of patient T cells, may affect manufacturing and
CAR T-cell efﬁcacy [10], this article focuses on the authors’ experiences and recommendations pertaining to overcoming the challenges
of obtaining optimal leukapheresis product for CAR T-cell
manufacturing from patients with B-cell malignancies. An algorithm
to improve leukapheresis collection efﬁciency is presented to better
predict the amount of processed blood volume required to minimize
the amount of time the patient spends in apheresis. Herein the
authors provide our experience based on CD19-targeted CAR T-cell

therapy and leukapheresis data from the larger tisagenlecleucel
manufacturing experience.
Challenges Associated with Leukapheresis
Patient evaluation and vascular access for leukapheresis
Prior to leukapheresis, patients are evaluated for their general
suitability to receive CAR T-cell therapy. The factors evaluated
include age, Eastern Cooperative Oncology Group performance status (ECOG PS) or Karnofsky/Lansky performance status, history of
prior malignancies, timing of prior alloSCT as it relates to immunosuppression status and graft-versus-host disease (GVHD), prior
CD19-directed therapy or CAR T-cell therapy clinical trials or commercial product, active infections and history of central nervous
system disease [7]. Beyond these initial patient and disease characteristics, clinical studies have also evaluated how patient characteristics may inﬂuence leukapheresis outcomes. In a retrospective
study of three clinical trials in pediatric patients with r/r B-cell
malignancies, 15% (n = 11, N = 71) of patients experienced leukapheresis complications, including paresthesia and nausea, but these
did not correlate with patient age or weight [13]. Similarly, in the
PLAT-02 and ENCIT-01 trials, age and weight (<40 kg versus >40
kg) in pediatric patients did not affect leukapheresis collection, but
the majority of patients (17 of 19, 89%) required a blood prime,
likely due to their total blood volume and low body weight [14].
Adult patients who have undergone CAR T-cell therapy in clinical
trials have also been evaluated for factors that may inﬂuence leukapheresis outcomes. In a single-center study among adult patients
with advanced B-cell malignancies (N = 92), having ALL, advanced
age and higher platelet counts were associated with poor leukapheresis collection efﬁciency [2]. The potential inﬂuence of other laboratory parameters that may indicate hepatic involvement or organ
failure, such as absolute neutrophil count, bilirubin, aspartate aminotransferase/alanine aminotransferase and serum creatinine
[7,15,16], and the subsequent effect on CAR T-cell product attributes are not well understood. Patient characteristics and collection
parameters that may affect leukapheresis collection efﬁciency were
evaluated at the Mofﬁtt Cancer Center in a retrospective study
among patients with r/r DLBCL treated with tisagenlecleucel [17].
In adult patients (N = 23), absolute lymphocyte count (ALC) and
peripheral blood CD3+ cell count signiﬁcantly correlated with leukapheresis product CD3+ cell counts (P < 0.0001 and P < 0.03,
respectively). The authors reported that high T-cell collection efﬁciency was possible among heavily pre-treated patients who had
received 3 prior lines of therapy and had low peripheral blood
lymphocyte counts (ALC <100/mL) provided that an adequate volume of blood was processed [17]. Patients with high circulating
blasts in peripheral blood may have difﬁculty meeting the leukapheresis product requirements for CD3+ cell count and CD3+%.
Overall, the authors found that peripheral blood ALC and CD3+ cell
counts were the best indicators of obtaining a sufﬁcient CD3+ cell
count in the leukapheresis product. An analysis of real-world leukapheresis and tisagenlecleucel manufacturing in young pediatric
patients (<3 years of age) with r/r ALL demonstrated improved outcomes from the ﬁrst US Food and Drug Administration approval of
a CAR T-cell product in 2017 through 2021 [8]. Based on these data,
some of the key author recommendations for optimizing leukapheresis in patients with low body weight included veriﬁcation of adequate ALC or CD3+ counts the day before leukapheresis,
maintenance of hematocrit levels at 40% prior to collection and
allowing more than 1 day for collection based on individual patient
needs [8].
Patient comorbidities and disease history may also affect leukapheresis outcomes. Current best practice recommendations for managing patients undergoing CAR T-cell therapy include pre-
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leukapheresis screening to assess eligibility and ﬁtness for CAR T-cell
therapy [18]. In clinical trials of CAR T-cell therapy, eligibility criteria
typically exclude patients with comorbidities that could have a negative impact on clinical outcomes, some of which could also affect leukapheresis and CAR T-cell manufacturing outcomes. However, in
real-world clinical practice, sicker patients with more severe comorbidities are being treated with CAR T-cell therapy and achieving clinical outcomes that are similar to those reported in CAR T-cell therapy
clinical trials. For example, an analysis of real-world data from 17
treatment centers in the United States found that patients with r/r
DLBCL underwent successful leukapheresis collections for the manufacture of axicabtagene ciloleucel (N = 298), even the 43% of patients
with comorbidities and baseline characteristics that would have
excluded them from participating in the registrational ZUMA-1 trial
of axicabtagene ciloleucel in adult patients with r/r large B-cell lymphoma. Criteria that would have resulted in exclusion from the
ZUMA-1 trial included ECOG PS >1, platelet count <75 000/mL, central nervous system disease, renal insufﬁciency, bilirubin >1.5 g/dL
and prior CD19-directed therapy [19]. Of these, ECOG PS, platelet
count and renal insufﬁciency should be evaluated prior to leukapheresis and may lead to adverse events (AEs) from leukapheresis,
including electrolyte imbalance and the need for transfusion. However, these AEs can typically be resolved with proper treatment [7]
and do not typically affect leukapheresis outcomes. Overall, CAR Tcell manufacturing was successful in 92% of patients who underwent
leukapheresis; however, the researchers noted lower progressionfree survival and overall survival among patients with comorbidities
that would have made them ineligible for ZUMA-1 [19].
During patient preparation for leukapheresis, vascular access
must be evaluated regardless of patient age, and assessment by experienced apheresis nurses can help determine the appropriate type of
access for each patient (i.e., peripheral versus central line). Peripheral
access considerations include vein location, integrity, elasticity, size
and whether the vein can support the blood ﬂow rates of an average
collection (85 mL/min) [20]. Central access is used if the patient’s
veins do not meet the standards for peripheral venous access. Among
pediatric patients who undergo collection of peripheral blood cells,
the majority require a central venous catheter to initiate and maintain blood ﬂow [21], including temporary or permanent tunneled
double-lumen apheresis catheters. The size of the catheter depends
on the patient’s weight; patients >30 kg can have either an 8-French
or a 10-French double-lumen catheter placed [14]. In the authors’
experience, a 7-French catheter has been used as the lower limit for
smaller patients. Although not routinely performed, the team performing leukapheresis collection determines if sedation is needed,
speciﬁcally for smaller pediatric patients or patients with clinical concerns. Potential complications that are monitored for during and after
collection include pneumothorax, bleeding, infection, electrolyte
issues (magnesium, calcium, potassium) and catheter site pain.
Among adult patients, leukapheresis collection using peripheral
venous access is common, but in cases where central catheter placement is needed, procedures are similar to those used for pediatric
patients.
Blood volume exchange and special considerations for speciﬁc
clinical management strategies depend on patient age/weight and
leukapheresis center guidelines and may include the need for transfusion, calcium supplementation and heparin use (additional details
regarding the use of anticoagulants are discussed later in this article).
Blood priming of the apheresis system using donated packed red
blood cells (PRBCs) should be considered for patients weighing
<25 kg to ensure that the patient is isovolemic during the collection
process. Blood prime in low-weight patients can compensate for
potentially high percentages (>15%) of extracorporeal blood volume
in the collection equipment, which can allow patients to remain stable and ensure that an adequate volume of blood is able to be processed during collection. To minimize potential contamination of the
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Table 1
Recommendations for optimizing leukapheresis in low-weight pediatric patients.
Timing

Actions

Before leukapheresis

Verify adequate ALC and/or CD3+ cell count day prior
to leukapheresis.
Transfuse PRBCs prior to leukapheresis to raise
hematocrit to 40% in patients <10 kg (preferably
<15 kg) to maintain hemodynamic stability during
procedure.
Blood prime leukapheresis instrument tubing with
irradiated and leukoreduced PRBCs for patients
<25 kg.
Anticoagulant with mixture of ACD-A and heparin to
minimize risk of ACD-Ainduced hypocalcemia.
Allow for >1 day of leukapheresis if needed to meet
acceptance criteria in small patients. Beneﬁts and
risks of additional days of leukapheresis (>1)
should be assessed on a case-by-case basis based
on leukapheresis product cell count (TNC and CD3
+). Risk to the patient must be collaboratively evaluated across the stem cell laboratory and clinical
teams.
Prevent hypothermia using warming blanket or inline blood warmer.
Observe patients for hypocalcemia, hypomagnesemia
and alkalosis (clinical signs and symptoms of irritability, inconsolable crying and heart rate and blood
pressure instability) by monitoring ionized calcium,
magnesium and blood gases and replacing as
needed and consider prophylactic IV calcium and
magnesium supplementation during the
procedure.
Monitor rate and color of in-line collection for nonmobilized MNC collection (maintain in-line salmon
color consistent with a leukapheresis product,
hematocrit at 34% and rate of approximately
0.81.2 mL/min or less in small children).
Monitor collection volume (not to exceed 10 mL/kg
per AABB standards) and perform partial rinse-back
at the end of each leukapheresis day. In low-weight
patients, four to six blood volume exchanges may
be necessary for adequate collection during a single
day of leukapheresis.

During leukapheresis

AABB, Association for the Advancement of Blood & Biotherapies; ACD-A, anticoagulant citrate dextrose solution A; ALC, absolute lymphocyte count; CD, cluster of
differentiation; IV, intravenous; MNC, mononuclear cell; TNC, total nucleated cell.
Provided courtesy of L. Cough [8,22].

leukapheresis product with T cells from the blood donor, leukoreduction ﬁlters and irradiation of PRBCs can be used to avoid transfer of
intact viable allogeneic T cells.
Pediatric patients with low body weight can present speciﬁc leukapheresis collection challenges and require speciﬁc optimization
strategies (Table 1) [8,22]. Recent experience with commercial tisagenlecleucel in 31 pediatric patients <3 years of age with r/r ALL and
low weight (<10 kg) identiﬁed factors for optimizing leukapheresis
[22,23]. For instance, raising the hematocrit to 40% with PRBCs may
be necessary to stabilize the patient during apheresis. Speciﬁcally,
the volume to be processed is based on linear regression of the target
number of CD3+ cells versus the number of peripheral CD3+ lymphocytes collected per volume of blood processed. The peripheral CD3+
lymphocyte count can be obtained through the patient pre-screening
process. Additional factors that can be optimized for leukapheresis in
patients weighing <10 kg include central venous catheter size, blood
prime of the leukapheresis instrument, hypothermia prevention during collection and an allowance of >1 day for collection (if needed)
[22,23].
During leukapheresis collection, the use of anticoagulants is necessary to maintain blood ﬂuidity in the apheresis system [24]. In this
setting, anticoagulant citrate dextrose solution A (ACD-A) is preferred, and although the permitted ratio of whole blood to ACD-A for
anticoagulants varies among institutions, a 12:1 ratio has been used
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as a default starting point. Smaller patients are at a higher risk of
hypocalcemia following leukapheresis when ACD-A is used as a result
of the typically higher number of blood volume exchanges during
leukapheresis resulting in an unacceptable level of ACD-A being
introduced to the patient. To reduce the risk of hypocalcemia, in conjunction with adjusting the ﬂow rate, heparin can be added to ACD-A
to decrease the citrate concentration to avoid clumping and maintain
ﬂuidity. In combination with heparin, using less ACD-A allows for a
higher inlet ﬂow and less time on the apheresis instrument [24].
Leukapheresis logistics
Timely coordination across the multidisciplinary team is necessary to achieve an efﬁcient leukapheresis collection [20]. Coordination can be improved by holding weekly team meetings that include
physicians, apheresis teams, nurses, pharmacists and social workers
[25]. In some instances, smaller patients and those with lower ALC
and CD3+ cells may require an additional leukapheresis collection
day. Pediatric and young adult patients, however, do not always
require additional collection. Teamwork and partnering between the
CAR T-cell therapy provider and manufacturer are essential in medically determining when and if additional collection days are necessary on an individual patient basis.
Successful manufacture of CAR T-cell products is dependent on
smooth coordination of supply chain logistics after collection. Leukapheresis sites must label material efﬁciently for processing and communicate with couriers to ensure proper handling procedures with
optimal cryogenic shippers with temperature control mechanisms
[25,26]. Speciﬁc areas of improvement for the manufacture of CAR Tcells include optimizing the T-cell enrichment process to reduce variability [27] and reducing the time taken to perform sterility testing
by using polymerase chain reaction-based mycoplasma sterility assay
[26]. The leukapheresis process needs to be as efﬁcient and timely as
possible to avoid disease progression and decline in patient performance status.
Leukapheresis product can be cryopreserved for long-term storage. For tisagenlecleucel, leukapheresis product is approved for cryopreserved storage for up to 30 months before manufacturing without
negatively affecting the post-thaw cell viability and recovery of
mononuclear cells (Novartis Pharmaceuticals Corporation data on
ﬁle). For hematopoietic progenitor cell transplant, some stem cells
have been reported to have been frozen for 15 years before use, with
post-thaw cell viability assessed by in vitro colony formation assays
[28]. It is possible that storage time for tisagenlecleucel leukapheresis
product could be extended in the future with the appropriate stability studies. For example, cord blood units can be stored for more than
20 years with minimal hematopoietic stem cell loss as assessed by
post-thaw in vitro colony formation and T-cell activity [29]. Because

of the ability to store leukapheresis product for longer-term periods,
there are opportunities for leukapheresis collections earlier in the
course of disease, which may correlate with higher cell counts and
quality, potential higher manufacturing success and a robust CAR Tcell product [10]. T-cell function (tumor necrosis factor alpha secretion in response to CD19 antigen) and expansion decrease with cycles
of chemotherapy [30,31]; therefore, earlier collection should be considered to ensure the highest possible activity for future cellular therapies.
Overall, cryopreservation ensures ﬂexibility for the timing of leukapheresis because the hold time for cryopreserved leukapheresis
cells used for tisagenlecleucel manufacturing has no effect on cell viability in the ﬁnal product [10]. In addition, cryopreserving leukapheresis product brings potential supply chain beneﬁts, including risk
mitigation against transportation interruptions or delays due to
unforeseen circumstances (e.g., current/future pandemics and severe
weather events), as cryopreserved cells are stable for long periods
compared with urgent fresh cell transport, which demonstrates
shorter viability timelines. Analysis of data from patients enrolled in
the ELIANA and JULIET clinical trials of tisagenlecleucel demonstrated
that leukapheresis cells collected and cryopreserved on the same day
had better post-thaw performance compared with cells that were
cryopreserved the day after leukapheresis collection [10]. Hold times
longer than 24 h before freezing had a negative effect on post-thaw
cell viability and signiﬁcantly reduced post-thaw cell recovery by up
to 20% in patients with DLBCL. In this study, the viability of T cells in
the post-thaw leukapheresis material was determined by microscopy
using trypan blue exclusion and calculated based on hemocytometer
counts [10]. In addition, the total number of CAR T cells during the
manufacturing process was consistently higher when leukapheresis
product was frozen on the same day as collection. In general, leukapheresis product performance was more negatively affected by a longer time between collection and cryopreservation, as characterized
by low cell viability following recovery of the cellular leukapheresis
product.
Characteristics of the leukapheresis product
Leukapheresis material must meet minimum speciﬁcations to be
accepted for tisagenlecleucel manufacturing, including CD3+ lymphocyte count, total nucleated cell (TNC) count and TNC CD3+% [32]. The
authors evaluated the relationship between characteristics of the
incoming leukapheresis product and CAR T-cell manufacturing success (deﬁned as sufﬁcient cell growth to achieve ﬁnal product speciﬁcations). Incoming leukapheresis material was characterized using
the following variables (when available): leukapheresis parameters,
sentinel vial measurements (% T cells, B cells, natural killer cells,
monocytes) and incoming apheresis cell counts (TNC, CD3+ count,

Fig. 1. Characteristics of leukapheresis products associated with successful CAR T-cell manufacturing. Apheresis products that result in successful CAR T-cell manufacturing have
more T cells and more less mature and less differentiated T cells than manufacturing batches that are terminated. Sentinel vial measurements included the percentage of T cells, B
cells, natural killer cells and monocytes. Incoming apheresis material measurements included total nucleated cells, total CD3 count and percent CD3+ cells. Effector T cells are shortlived and actively secrete cytokines. Effector memory T cells are responsible for cytotoxic action against pathogens and are typically found in the peripheral circulation and tissues.
Central memory T cells augment immune response after reactivation and are typically found in the peripheral circulation and lymph nodes (Novartis Pharmaceuticals Corporation
data on ﬁle). CM, central memory T cells; Effector, effector T cells; EM, effector memory T cells; HLA-DR, human leukocyte antigen - DR isotype; inc. aph, incoming apheresis material; KLRG1, killer cell lectin-like receptor G1; LKPK, leukapheresis material (tisagenlecleucel starting material); SENT, sentinel vial. Provided courtesy of Novartis Pharmaceuticals
Corporation.
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Fig. 2. Recommended washout periods prior to leukapheresis for CAR T-cell manufacture and timing for discontinuation of prior therapy if the patient’s condition and disease status
allow. Recommendations are based on previously published guidance [7,39] and the authors’ clinical experience. aIf indicated, intrathecal cytarabine can be given up to a day prior
to leukapheresis. For an intravenous cytarabine dose <100 mg/m2, a washout of 7 days is recommended; for a dose 100 mg/m2, a washout of 14 days is recommended. bFor bendamustine and ﬂudarabine, allow adequate washout and avoid use for 12 weeks prior to leukapheresis because of the potential long-term effects on T cells; however, limited data
are available for these agents in the context of CAR T-cell therapy for these agents. cFor alemtuzumab and ATG (T-cell lytic agents), allow adequate washout, avoid use for 6 months
prior to leukapheresis and consider the potential prolonged effects on T cells. dAlthough the half-life of blinatumomab is short (approximately 2 h), a washout of 12 weeks is recommended prior to leukapheresis. The inotuzumab elimination half-life (12.3 days) is too long to wait for a washout period of ﬁve half-lives in most patients. ATG, anti-thymocyte
globulin; GVHD, graft-vs-host disease; HU, hydroxyurea; pALL, pediatric acute lymphoblastic leukemia. Provided courtesy of Novartis Pharmaceuticals Corporation. Copyright
Novartis Pharmaceuticals Corporation 2021.

CD3+%). The relative importance of the leukapheresis variables for
manufacturing success was assessed using univariate (box plots, Wilcoxon signiﬁcance test, adjusted P values) and multivariate (decision
tree/random forest, logistic regression, elastic net) analyses. In general, patients with T cells that are less mature and less differentiated
at collection tend to achieve more successful manufacturing outcomes than patients with more mature and more differentiated/activated T cells (Figure 1). Overall, successful tisagenlecleucel
manufacturing for patients with DLBCL has been associated with the
collection of more T cells and tends to include T cells that are less
mature and less differentiated and exhibit higher expression of CD25
(e.g., naive/stem memory T cells [TSCMs], naive/TSCMs + memory T
cells, early differentiated T cells and TSCM-like cells; Figure 1).
Because terminated batches often have higher expression of activation markers (HLA-DR or HLA-DR and CD38), which are also upregulated upon T-cell activation, the lower expression of CD25 observed
in terminated batches may be due to decreased IL-2 uptake, which
can negatively impact T-cell growth.
Terminated batches (in which manufacturing failed) often have
more mature and differentiated T cells (including killer cell lectinlike receptor G1+ cells, terminally senescent effector memory cells
and activated HLA-DR+/CD38+ and HLA-DR+ T cells), more B-lineage
cells (including lymphoblasts) and more TNCs. Killer cell lectin-like
receptor G1+ expression increases with patient age, reaching 90% on
CD8+ T cells in individuals >65 years [33], and increases with T-cell
maturation, with the highest expression seen in differentiated endstage cells [34]. Similarly, among pediatric and young adult patients
with ALL, successful tisagenlecleucel manufacturing has been associated with the collection of more total T cells, with a higher proportion
of T cells that are less mature and less differentiated, and CD4+ T cells,
with a higher ratio of CD4+:CD8+ cells. The results observed in
patients with pediatric ALL are consistent with recent data showing
that the maturation and differentiation states of T-cell subpopulations have an impact on the manufacture of CAR T-cell products
[30,35]. In general, a less mature and less differentiated T-cell subtype is beneﬁcial for generation of proliferating CAR T cells. Leukapheresis material enriched for naive and stem central memory T cells
expanded well in vitro, but studies have shown chemotherapyrelated depletion and a corresponding decline in T-cell expansion
[30,35].

Leukapheresis is used to obtain T cells from the patient’s peripheral blood for CAR T-cell manufacturing; however, as the leukapheresis collection separates blood components by density gradient, the
process yields a variety of cells and not a pure CD3+ T-cell product.
Monocytes in the leukapheresis collection material have been considered contaminants because they eventually become macrophages
and may engulf and digest cellular constituents, including the antibody-conjugated beads used for CAR T-cell manufacturing [36].
Therefore, monocyte contaminants may result in a reduction in the
viable CAR T-cell counts required to meet dosing requirements in the
ﬁnal product. Granulocyte colony-stimulating factors prescribed to
patients post-chemotherapy and radiation to mitigate neutropenia
can affect cell populations (e.g., increased levels of monocytes) [37],
which may alter ﬁnal CAR T-cell counts and expansion potential. For
these reasons, protocols have been developed to deplete myeloid
cells by plastic adherence [13]. Circulating tumor cells in patients
with ALL, chronic lymphocytic leukemia and non-Hodgkin lymphoma contribute to higher B-cell and toxic malignant cell counts
that can interfere with healthy T-cell numbers and expansion. Therefore, treating physicians should provide therapy to reduce the number of circulating blasts prior to leukapheresis, especially in pediatric
ALL patients with very high circulating blast counts, underlying
chronic lymphocytic leukemia and/or circulating DLBCL blasts.
Washout of medications prior to leukapheresis
Patients with r/r B-cell ALL and DLBCL have likely received prior
aggressive chemotherapies and/or high-dose steroids that can have a
detrimental effect on patients' T cells. Therefore, appropriately timed
washout of chemotherapy, medications and other agents prior to leukapheresis collection is important to optimize T-cell ﬁtness and
achieve manufacturing success. For the majority of anti-neoplastic
agents, a washout period equal to ﬁve half-lives for the particular
agent/drug has been suggested to allow for sufﬁcient clearance to
obtain optimal leukapheresis collection material (Figure 2)
[7,22,38,39]. However, agents that directly affect T cells or CD19
expression may require a washout period longer than ﬁve half-lives
[7,22,39].
Based on individual agent/drug half-lives and the known or
potential effects on T-cell ﬁtness, short-acting cytotoxic, anti-
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proliferative drugs can be administered up to 3 days prior to leukapheresis [7]. Short-acting growth factors and nilotinib should have a
washout period of 5 days prior to leukapheresis, with the washout
period being longer than ﬁve half-lives of the therapeutic agents.
Intrathecal methotrexate, therapeutic doses of steroids (especially
dexamethasone) [7] and lenalidomide are recommended to be discontinued at least 7 days prior to leukapheresis. However, steroids
used for physiological replacement require no washout [7]. This
includes <12 mg/m2/day and <40 mg/day of hydrocortisone or
equivalent in pediatric patients and adult patients, respectively [32].
At 14 days prior to leukapheresis, systemic chemotherapy and GVHD
therapies [39], long-acting growth factors, tyrosine kinase inhibitors
with known effects on T-cell function and proliferation (imatinib
[40,41], dasatinib [42,43], ponatinib), inotuzumab and blinatumomab
should be discontinued. Adherence to a washout period of at least
14 days for systemic GVHD therapies allows patients with chronic
GVHD to undergo leukapheresis collection [39]. However, for patients
with chronic GVHD receiving topical or inhaled steroids, care must be
taken to ensure there is no active GVHD at leukapheresis, as this may
affect CAR T-cell manufacturing. Donor lymphocyte infusion should
be completed and pegylated asparaginase should not be given within
4 weeks of leukapheresis [7]. Therapy with clofarabine and T-cell lytic
agents should be terminated 8 weeks before leukapheresis, and
alloSCT should be completed at 12 weeks prior to leukapheresis as a
general guideline. The half-life of polatuzumab may be too long to
wait ﬁve half-lives for washout [44]; therefore, a washout period of
at least 12 weeks is recommended. Bendamustine may have a prolonged effect on the suppression of hematopoiesis and depletion of
lymphocytes [45,46] and, along with ﬂudarabine therapy [47], should
be discontinued at least 12 weeks before leukapheresis. Rituximab
washout is not required if the patient’s condition and disease status
do not allow adequate washout, as the half-life may be too long to
wait (2232 days) [48]. Although polatuzumab, bendamustine, rituximab and ﬂudarabine may have long-term effects on T cells, limited
data are available in the context of CAR T-cell therapy [39]. In general,
the use of CD19-targeted therapies should be avoided, as they may
negatively impact CAR T-cell outcomes and increase the risk of
CD19 clone selection. Tafasitamab has a long half-life (17 days) and
is a CD19-targeted antibody. Thus far, in vitro studies have shown
that the CD19 antigen (CAR T-cell therapy target) is still present after
tafasitamab treatment [49]. Figure 2 provides guidance for leukapheresis washout periods, but the patient’s disease status and overall
condition should always be considered when determining the best
time for drug washout and leukapheresis collection. Collectively, leukapheresis washout guidelines are constantly evolving as new agents
become available and will require further evaluation as our understanding of their potential effects on T-cell function evolves.
AE management during leukapheresis
Leukapheresis has long been performed in the outpatient setting
without serious complications, and many AEs can be prevented by
thorough patient assessments prior to apheresis. Vasovagal/hypovolemic reactions, air embolus, extracorporeal hemolysis, citrate toxicity
or tetany, hematoma and general mild reactions (e.g., headache, muscle cramping, irregular pulse, mild allergic reaction) are some of the
AEs that may be reported during the leukapheresis process. AEs during
the leukapheresis process are generally infrequent but are more common in younger patients and patients with comorbidities. The standard operating procedure of the University of Kansas Health System's
Department of Pathology and Laboratory Medicine for managing these
apheresis-related AEs depends on the nature of the reaction [50]. Typically, the health care professional will assess the patient and decide if
the leukapheresis procedure should be discontinued. A rapid response
team may be activated if the patient requires cardiopulmonary resuscitation or if there is a deterioration in the patient’s condition that

requires additional attention. Electrolyte management is essential during leukapheresis and includes ionized calcium and magnesium monitoring. The most common AEs include citrate reactions
(hypocalcemia), post-procedure fatigue, syncope, transient loss of consciousness, hypotension, nausea, vomiting and diaphoresis [51,52] and
can be prevented or managed with standard leukapheresis procedures.
AEs reported during leukapheresis for CAR T-cell therapy are similar in
type and frequency to those reported during stem cell apheresis for
stem cell transplants [51,53]. Data on apheresis-associated AEs are currently being collected in CAR T-cell therapy clinical trials (e.g., CASSIOPEIA, COG AALL1721, ELARA, BELINDA) and may be valuable in further
optimizing patient safety during collection. Acquisition of data from
these clinical trials with regard to T-cell ﬁtness and timing of collection
is ongoing. Overall, AEs during leukapheresis are manageable and do
not pose a barrier for CAR T-cell therapy.
Achieving adequate cell counts with leukapheresis
Appropriate ALC and/or CD3+ cell counts in the peripheral blood
prior to leukapheresis are recommended to avoid failure of T-cell collection for CAR T-cell production. In a small single-institution study
(N = 23), tisagenlecleucel manufacturing was successful even in
heavily pre-treated adult patients with r/r DLBCL who underwent
leukapheresis and patients with very low ALC (<100/mL) [17]. In two
separate trials (PLAT-02 and ENCIT-01) that had the same apheresis
collection parameters, pediatric patients (N = 99) were required to
have ALC >100/mL in the peripheral blood, platelet count >50 000
and hematocrit 25% regardless of whether blood prime was utilized
for CAR T-cell production [14]. The researchers concluded that an
adequate number of CD3+ T cells in the apheresis product can be
obtained even in heavily pre-treated patients with low lymphocyte
counts (ALC <500/mL) [14]. In a retrospective study across three trials, pediatric patients (N = 71) with ALC <1.5 £ 103/mL yielded less
than the target number of CD3+ cells, and researchers concluded that
these patients may require processing of larger blood volumes [13].
Overall, the observed correlation between pre-collection CD3+ lymphocytes and successful leukapheresis has led some centers to set
ALC thresholds between 100/mL and 500/mL and a minimum of 150/
mL for CD3+ T cells [54].
In adult patients with DLBCL and young adults with ALL who are
undergoing leukapheresis for CAR T-cell manufacturing, depending
on ALC at the time of leukapheresis, two to four total blood volumes
are typically adequate to achieve a successful leukapheresis collection. If ALC or peripheral CD3+ cell counts are low, it may be necessary to increase the total blood volume collected; alternatively, more
than 1 day of collection may be required. Other parameters recommended to optimize leukapheresis collection in these patients
include having a pre-leukapheresis hematocrit >26% and a platelet
count >30 000/mL. In some cases involving both small pediatric
patients and older DLBCL patients, an additional collection day may
be required to obtain adequate leukapheresis product to achieve sufﬁcient cell counts [22,23]. Likewise, when there are 90% blasts in
the peripheral blood and/or low CD3 and ALC because of prior therapy, there may be a need for delayed collection until the patient
exhibits a more stable clinical status. However, in patients with
highly refractory disease, it may be advantageous to proceed with 2day leukapheresis. Patients with GVHD are commonly lymphopenic,
making peripheral blood draws challenging [55]; thus, steady-state
peripheral blood draws have been recommended for GVHD patients.
Patients who undergo leukapheresis for CAR T-cell manufacturing
must achieve designated collection yield requirements that can be different for different product manufacturers, varying from speciﬁc cell counts
to more general requirements for a pre-speciﬁed volume of blood processed. Tisagenlecleucel requirements for leukapheresis product include
speciﬁc collected cell counts for CD3+ lymphocytes (1 £ 109 CD3+ cells),
TNCs (2 £ 109) and TNC CD3+% (3%) (Table 2). In the authors’
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Table 2
Leukapheresis speciﬁcations for CAR T-cell manufacturing.
Tisagenlecleucela
CD3 count
TNC count
CD3/TNC%

1 £ 109
2 £ 109
3%

General CAR T-cell leukapheresis guidanceb
ALC
Total blood volume processed
100 cells/mL
>100 cells/mL but <300 cells/mL
>300 cells/mL but <500 cells/mL
>500 cells/mL but <1000 cells/mL
>1000 cells/mL

Consider 2-day collection
3.54£
3£
2.5£
1.5£

CAR, chimeric antigen receptor; CD, cluster of differentiation; TNC, total
nucleated cell.
a
Provided courtesy of Novartis Pharmaceuticals Corporation.
b
Based on the authors’ clinical experience.

experience, the measured cellular constituent counts are often rounded
up in very small children, and this has not affected ALL CAR T-cell
manufacturing outcomes, although an optimal cell count of 1.5 £ 109 to
4 £ 109 has been found to improve DLBCL CAR T-cell manufacturing outcomes. Alternatively, leukapheresis product requirements for other CAR
T-cell therapies specify only blood volume to process.
At the University of Kansas Cancer Center, physicians have
devised guidance for leukapheresis blood volume collections based
on the patient’s ALC (Table 2). Based on discussions with several leukapheresis centers, the use of deﬁned cell counts is generally preferred to guarantee that a sufﬁcient amount of material has been
collected. An analysis of leukapheresis products that did not meet
speciﬁcations found that they were associated with smaller blood
volumes processed, shorter run times and smaller apheresis product
volumes in patients with r/r DLBCL (N = 23) [17]. Overall, patients
with low ALC and peripheral blood CD3+ cell counts were still able to
obtain adequate CD3+ cell collection in the leukapheresis product
[17]. Determining peripheral blood lymphocyte counts not more
than 1 day prior to leukapheresis collection can aid in optimizing
processed volumes and run times.
Methods for increasing the quality (ﬁtness) and yield of T cells
expanded from apheresis products of heavily pre-treated patients
with r/r DLBCL and overall lower T cell counts should be explored. In
support of this idea, an analysis of biomarker data from the ZUMA-1
trial of axicabtagene ciloleucel found that T-cell ﬁtness in the ﬁnal
CAR T-cell product (estimated by global doubling time in culture)
was associated with response [56]. Other studies have shown that
prior therapy can affect T-cell ﬁtness, and patients with DLBCL who
received multiple rounds of chemotherapy had increased CD27 and
CD28 senescence, resulting in lower T-cell expansion and viability
when cultured with anti-CD3/CD28 beads [57]. Antagonism of
certain pathways may have inﬂuenced the expansion of polyfunctional T cells, improving the leukapheresis product collected from
heavily pre-treated patients. Antagonism of vasoactive intestinal
peptide signaling in combination with inhibition of phosphatidylinositol 3-kinase delta decreased T-cell differentiation during
bead-mediated expansion, resulting in a signiﬁcant increase in
the number of T cells (83.7%) cultured from lymphoma patients
[57].
Improving leukapheresis collection efﬁciency

Fig. 3. Linear regression analysis of actual versus predicted leukapheresis collection.
Relationship between actual yield of CD3+ cells collected during the data collection
phase (10 procedures) and algorithm-predicted yield of CD3+ cells. The dashed line
represents the linear regression between actual collected cells and predicted yield.
Provided courtesy of Avera Medical Group, 2021.

the baseline peripheral blood CD3+ cell count can be used to estimate
collection efﬁciency and customize the length of leukapheresis for
each patient [13]. Determining the leukapheresis parameters for optimal collection efﬁciency is especially important for low-weight/pediatric patients. A retrospective analysis of heavily pre-treated
pediatric patients with r/r ALL found that baseline peripheral blood
CD3+ counts were variable and did not correlate with the patient’s
age or previous therapies [59]. Despite low T-cell collection efﬁciency, most patients achieved the target T-cell count needed for
manufacture [59]. Another retrospective analysis evaluated collection
efﬁciency in a cohort of heavily pre-treated pediatric patients with r/r
ALL, lymphoma and neuroblastoma from two CAR T-cell therapy trials [14]. The planned collection volume was based on the total mononuclear cell count, and the researchers acknowledged that this
method underestimated or overestimated the T-cell collection efﬁciency based on the wide range of CD3+ T-cell recovery observed
(32623%). Despite the wide range in collection efﬁciency, an adequate number of T cells were able to be collected in these patients.
Overall, these retrospective studies suggest that leukapheresis has
been safe and effective despite highly variable collection efﬁciency;
however, methods to improve collection efﬁciency using a prediction
algorithm may be beneﬁcial. Several groups have developed prediction algorithms to optimize collection efﬁciency and tailor the volume of blood processed to collect the desired target cell counts, with
a goal of avoiding undercollection and preventing the need for additional collection days [60].
The Avera Medical Group developed a collection algorithm that routinely achieves 74% collection efﬁciency. Based on their experience, the
group also devised a leukapheresis prediction model that demonstrated
a high correlation between the predicted and actual number of cells collected (Figure 3). This suggests that this prediction model may be useful
in determining which patients’ T cells can be successfully collected and
the amount of time needed for collection. The predictive collection algorithm was developed after performing 10 leukapheresis procedures
using the processing volume recommended by the manufacturer. To
better predict leukapheresis collection efﬁciency, validation for use in
clinical practice must be further explored. The collection efﬁciency for
each procedure was determined as follows:
Collection efficiencyðCEÞð%Þ ¼
Total CD3 þ lymphocyte count in

An established leukapheresis collection algorithm can improve
collection success and prevent overcollection. Collection efﬁciency
can be affected by several factors during leukapheresis, including
higher platelet counts, high numbers of circulating malignant cells
and the patient’s age [58]. A retrospective analysis of leukapheresis
outcomes from three clinical trials of CAR T-cell therapy found that

Peripheral CD3þ
lymphocyte count
ðcells=mLÞ

leukapheresis material CD3þ ðcellsÞ
6

 10

mL=L  Total blood volume processed ðLÞ

 100
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The mean collection efﬁciency of the 10 procedures was calculated to be 74%. The target CD3+ yield was set to 4 £ 109 cells—higher
than the recommendation for tisagenlecleucel (1 £ 109)—to allow
for a margin of error. The estimated blood volume needed to process
the target CD3+ yield was calculated as follows:

Table 3
Key considerations for leukapheresis collection to ensure optimal T-cell ﬁtness
and promote CAR T-cell manufacturing success.
Timing

Considerations

Before leukapheresis

 Consider leukapheresis and cryopreservation early
in the course of disease for patients with aggressive/high-risk disease.
 Appropriately timed washout of chemotherapy,
medications and other agents prior to leukapheresis collection is important to optimize T-cell ﬁtness.
 Provide therapy to reduce the number of circulating blasts prior to leukapheresis for patients with
high disease burden (when possible).
 Verify adequate ALC and/or CD3+ cell count day
prior to leukapheresis.
 Evaluate the need for a second day of collection
using prediction algorithm.
 Take into account patient-speciﬁc considerations
(e.g., infants).
 Cryopreservation of leukapheresis material the
same day as collection can improve post-thaw cell
viability and manufacturing outcomes.
 Verify that post-collection leukapheresis speciﬁcations for CAR T-cell manufacturing have been met.

Target CD3þ yield ðcellsÞ
Blood volume ðLÞ ¼
Peripheral CD3þ
lymphocyte count  106 mL=L  Mean CE ð%Þ
ðcells=mLÞ

Following 10 collections, the leukapheresis prediction algorithm
was used to compare the actual CD3+ yields with predicted CD3+
yields. The predicted yield for each collection was calculated by
substituting the actual total blood volume (L), peripheral CD3+ lymphocyte count (cells/mL) and mean collection efﬁciency (%). A strong
linear correlation (R2 = 0.9635) between the collected CD3+ cells and
the predicted CD3+ value was observed (Figure 3). Based on the
strong linear correlation, the authors were able to successfully use
the prediction algorithm in subsequent leukapheresis collection procedures.

After leukapheresis

Excess leukapheresis product
It is possible for a robust leukapheresis collection to result in collection of more cells than are needed for manufacturing. There are
several theoretical options that may be available for patients with
excess leukapheresis product, including the potential to provide consent to donate excess cells to research or to store excess cells for
potential future use. Storage of excess cryopreserved leukapheresis
product may be possible at some treatment centers or manufacturers,
and in some cases it may be possible to store cells at independent
storage cell banks. The ability to store excess leukapheresis product
at a treatment center or manufacturer is largely dependent on the
practices of the treatment center or manufacturer and the availability
of storage space. There may be costs associated with the storage of
cells, and in some cases the willingness of patients to pay for longterm storage may be a factor.
Discussion
Herein the authors have provided guidance for improved leukapheresis for CAR T-cell manufacturing based on our clinical experience. Optimization of the leukapheresis process is clearly important
for achieving a high rate of CAR T-cell manufacturing success. A basic
requirement for CAR T-cell manufacturing is the ability to collect a
sufﬁcient number of viable T cells during leukapheresis. Leukapheresis collection may be optimized in several ways to achieve high CAR
T-cell manufacturing success, including via appropriate staff training,
alignment of collection days with manufacturing availability, potential collection of patient cells earlier during the course of the disease,
appropriate washout of prior therapies to minimize potential negative effects on T cells, utilization of a prediction algorithm to improve
leukapheresis collection efﬁciency, same-day shipment or cryopreservation of the leukapheresis product following collection and observation of recommendations for collection from pediatric patients
with low body weight (Table 3).
Conclusions
A deeper understanding of the potential inﬂuence of prior therapies on leukapheresis collection and CAR T-cell therapy outcomes is
needed. Future studies that evaluate the phenotype of T cells in
peripheral blood prior to leukapheresis and determine the immunomodulatory effects of chemotherapy on T cells will be beneﬁcial in
further optimizing leukapheresis collection for CAR T-cell therapy. As
our understanding grows through knowledge gained from clinical

trials and real-world experience, the timing and mechanics of leukapheresis and processing of the leukapheresis product will likely be
further optimized to achieve the best possible outcomes for our
patients.
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